HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Mr Paul Hopper

Executive Chairman

Paul Hopper has more than 20 years’ experience in international public company markets, with a focus on start-up and rapid growth companies where he has served as either Chairman, Non-Executive Director or CEO. His focus has been primarily in the life-sciences sector, steering around fourteen public companies in the US, Australia, and Asia.

Paul is an advisor at the Los Angeles-based Cappello Group where he is Head of the Life Sciences and Biotechnology Group responsible for mergers and acquisitions and capital raisings focusing on the biotechnology and life sciences sectors.

He is a Non-Executive Director of Prescient Therapeutics Ltd, Chairman of Viralytics Ltd and founder of Pathway Oncology.

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551